Regulatory Status

Oncology

ZetaMet™
(Zeta-BC-003)

ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, developed via a proprietary control release carrier developed to resolve bone lesions, inhibiting pain while regenerating bone, with the potential to increase survival rates. The U.S. Food and Drug Administration recently awarded ZetaMet™ (Zeta-BC-003) Breakthrough Designation for the treatment of metastatic bone cancer. Currently, ZetaMet™ (Zeta-BC-003) has been approved by Health Canada for a clinical trial which is currently enrolling for the treatment of metastatic breast cancer lesions to the spine. Zetagen scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions.
Enrollment for this study is scheduled for Q1-2024.

ZetaMet-P™
(Zeta-PC-004)

ZetaMet-P™ (Zeta-PC-004) is a synthetic, small-molecule, antitumorigenic therapy, administered locally, being developed to target and resolve metastatic prostate cancer bone lesions while inhibiting future tumor growth. The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971 and has an extensive safety profile.

ZetaMAST™
(Zeta-MBC-005)

ZetaMAST™ (Zeta-MBC-005) is a proprietary novel drug being designed for patients with unresectable, multifocal breast cancer metastases to the liver. ZetaMAST™ (Zeta-MBC-005) can be administered as a percutaneous injection utilizing a proprietary hydrogel carrier containing a precise, tailored concentration of our small molecule. Preclinical studies have demonstrated ZetaMAST™ (Zeta-MBC-005) may cease lesion growth, with the goal of enabling improved quality of life as part of a cancer treatment program, including longevity.

ZetaBase®

ZetaBase® is the carrier for ZetaMet™ (Zeta-BC-003) and is osteo-conductive and osteo-promotive, specifically formulated to aid bone healing in the treatment of metastatic lytic bone lesions. ZetaBase® may also be used as a bone void filler and or bone graft extender to fill bony voids or gaps that are not intrinsic to the stability of bony structures. ZetaBase® Bone Graft will be available in various sizes and is provided sterile, non-pyrogenic, and for single use only

Musculoskeletal

ZetaFuse™

ZetaFuse™ is the first synthetic, small molecule, osteo-inductive biologic, to safely aid bone healing of spinal fusions. The FDA has awarded ZetaFuse™ Breakthrough Device Designation[1] for the complete spinal column.

ZetaSet™

ZetaSet™ is the first synthetic, osteo-inductive, biologic designed specifically for the treatment of osteoporotic fractures, high energy injuries with bone defects, and for patients with fractures of the tibial plateau (knee) and plafond (ankle).

ZetaBase®

ZetaBase® is an osteo-conductive and osteo-promotive therapy, intended for the use as a bone void filler for bony voids or gaps that are not intrinsic to the stability of the bony structure. Pending 510K approval 2H-2022.

Craniomaxillofacial

ZetaDent™

ZetaDent™ is an osteo-inductive biologic intended to promote bone formation as a part of localized ridge augmentation procedures prior to dental implant placement, alveolar ridge reconstruction procedures for prosthetic treatment, and for filling of bone defects in the oral cavity.

ZetaSet™

Clinical Trials

Now Enrolling

1.

ZetaMet™ (Zeta-BC-003) Bone Graft in the Repair of Bone Defects From Metastatic Breast Cancer in the Spinal Vertebral Body (CTN - NCT05280067)

2.

Pilot Study of ZetaFuse™ (Zeta-ZF-002) Bone Graft for the Treatment of Cervical Degenerative Disc Disease (CTN - NCT05971329)